09619493

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 2, 2004 (20040702/UP).

=> file reg
COST IN U.S. DOLLARS — SINCE FILE ENTRY: 0.06 — TOTAL SESSION: 0.27
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:27:34 ON 09 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUL 2004 HIGHEST RN 706430-72-0
DICTIONARY FILE UPDATES: 8 JUL 2004 HIGHEST RN 706430-72-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s drospirenone
L1 2 DROSPIRENONE

=> d l1 1-2

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 164017-31-6 REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with
(2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16
,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclop
enta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX
NAME)
OTHER CA INDEX NAMES:
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with
[6R-(6α,7α,8β,9α,10β,13β,14α,15.alp
ha.,16α,17β)]-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]
phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione
CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-
furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10.
beta.,13β,14α,15α,16α,17β)]-, mixt. contg.
CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-
furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-,
mixt. contg. (9CI)
OTHER NAMES:
CN **Drospirenone-ethinylestradiol mixt.**

09619493

CN **Ethinylestradiol-drospirenone mixt.**
CN Yasmin
FS STEREOSEARCH
MF C24 H30 O3 . C20 H24 O2
CI MXS
SR CA
LC STN Files: ADISNEWS, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, DIOGENES, EMBASE, IMSPATENTS, IMSRESEARCH, PROMT, PROUSDDR, TOXCENTER, USPATFULL
DT.CA CAplus document type: Book; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



29 REFERENCES IN FILE CA (1907 TO DATE)
29 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN

7/9/04

09619493

RN 67392-87-4 REGISTRY
CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, [6R-(6α,7α,8β,9α,10.beta.,13β,14α,15α,16α,17β)]-
OTHER NAMES:
CN 1,2-Dihydrospirorenone
CN 3-Oxo-6β,7β:15β,16β-dimethylene-17α-pregn-4-en-21,17-carbolactone
CN BRN 4765500
CN CCRIS 6523
CN Dihydrospirorenone
CN Drospirenona
CN **Drospirenone**
CN ZK 30595
FS STEREOSEARCH
MF C24 H30 O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMLIST, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Book; Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7/9/04

122 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
123 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s progesterone
L2 1355 PROGESTERONE

=> d l2 1-2

L2 ANSWER 1 OF 1355 REGISTRY COPYRIGHT 2004 ACS on STN
RN 685528-52-3 REGISTRY
CN **Progesterone, 11α-hydroxy-6α-methyl- (6CI)** (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H32 O3
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: NORL (No role in record)
RL.NP Roles from non-patents: NORL (No role in record)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 1355 REGISTRY COPYRIGHT 2004 ACS on STN
RN 672548-65-1 REGISTRY
CN **Progesterone receptor (human) (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN 30: PN: WO2004022750 SEQID: 15 claimed protein
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:H
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      17.62      17.89

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:30:04 ON 09 JUL 2004

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1202sxq

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 16:35:31 ON 09 JUL 2004
FILE 'REGISTRY' ENTERED AT 16:35:31 ON 09 JUL 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      17.62      17.89

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      17.62      17.89

FILE 'CAPLUS' ENTERED AT 16:35:46 ON 09 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 9 Jul 2004  VOL 141 ISS 3
FILE LAST UPDATED: 8 Jul 2004  (20040708/ED)
```

09619493

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1
L3          141 L1

=> s l1 and estradiol
            141 L1
          71124 ESTRADIOL
L4           56 L1 AND ESTRADIOL

=> s l1 and estrogen
            141 L1
          67954 ESTROGEN
L5           52 L1 AND ESTROGEN

=> s l4 and depression
          69342 DEPRESSION
L6            2 L4 AND DEPRESSION

=> mood swings
MOOD IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s mood swings
           4668 MOOD
            699 SWINGS
L7           53 MOOD SWINGS
                (MOOD(W)SWINGS)

=> s l1 and l7
            141 L1
L8            0 L1 AND L7

=> s l3 and l7
L9            0 L3 AND L7

=>  s l4 and l7
L10           0 L4 AND L7

=> s l1 and irritability
            141 L1
           1767 IRRITABILITY
L11           1 L1 AND IRRITABILITY

=> s ll1 and anxiety
            128 LL1
          11444 ANXIETY
L12           0 LL1 AND ANXIETY

=> s l1 and depression
            141 L1
          69342 DEPRESSION
L13           4 L1 AND DEPRESSION

=>
=> s l1 and headaches
```

7/9/04

```
           141 L1
          1249 HEADACHES
L14          1 L1 AND HEADACHES

=> s l3 and headaches
          1249 HEADACHES
L15          1 L3 AND HEADACHES

=> s l1 and insomia
           141 L1
             3 INSOMIA
L16          0 L1 AND INSOMIA

=> d his

     (FILE 'HOME' ENTERED AT 16:27:14 ON 09 JUL 2004)

     FILE 'STNGUIDE' ENTERED AT 16:27:17 ON 09 JUL 2004

     FILE 'REGISTRY' ENTERED AT 16:27:34 ON 09 JUL 2004
L1             2 S DROSPIRENONE
L2          1355 S PROGESTERONE

     FILE 'CAPLUS' ENTERED AT 16:35:46 ON 09 JUL 2004
L3           141 S L1
L4            56 S L1 AND ESTRADIOL
L5            52 S L1 AND ESTROGEN
L6             2 S L4 AND DEPRESSION
L7            53 S MOOD SWINGS
L8             0 S L1 AND L7
L9             0 S L3 AND L7
L10            0 S L4 AND L7
L11            1 S L1 AND IRRITABILITY
L12            0 S LL1 AND ANXIETY
L13            4 S L1 AND DEPRESSION
L14            1 S L1 AND HEADACHES
L15            1 S L3 AND HEADACHES
L16            0 S L1 AND INSOMIA

=> s l1 and premenstrual
           141 L1
          1157 PREMENSTRUAL
L17          11 L1 AND PREMENSTRUAL

=> s l4 and prementrual
             0 PREMENTRUAL
L18          0 L4 AND PREMENTRUAL

=> s l3 and premenstrual
          1157 PREMENSTRUAL
L19          11 L3 AND PREMENSTRUAL

=> s l1 pmdd
MISSING OPERATOR L1 PMDD
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l1 and pmdd
           141 L1
            57 PMDD
```

09619493

```
L20           1 L1 AND PMDD

=> s l1 and pms
            141 L1
           3166 PMS
L21            0 L1 AND PMS

=> s l3 and pms
           3166 PMS
L22            0 L3 AND PMS

=> d l6 1-2 ibib hitstr abs

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2003:796500  CAPLUS
DOCUMENT NUMBER:          139:271458
TITLE:                    Pharmaceutical compositions and uses for hormone
                          replacement therapy with estrogenic and progestogenic
                          compounds coupled to an aromatase inhibitor
INVENTOR(S):              Casper, Robert F.
PATENT ASSIGNEE(S):       Jencap Research Ltd., Can.
SOURCE:                   PCT Int. Appl., 75 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2003082299      A1   20031009       WO 2003-CA491    20030403
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
             GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                    US 2002-369629P  P  20020403
                                          US 2002-369707P  P  20020403
IT   67392-87-4, Drospirenone
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (pharmaceutical compns. and uses for hormone replacement therapy with
       estrogenic and progestogenic compds. coupled to an aromatase inhibitor)
RN   67392-87-4  CAPLUS
CN   Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-
     furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
     hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-
     (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



AB The present invention provides an improved pharmaceutical preparation, for administration to a female in need of hormone replacement therapy with substantially reduced breakthrough bleeding, comprising a plurality of doses wherein each dose comprises an amount of a substance exhibiting estrogenic activity and an amount of a substance exhibiting progestogenic activity and at least one aromatase inhibitor. The use of those compns. are exemplified on women presenting premature ovarian failure, normal menopause and ovariectomy removed following endometriosis. Effects on breast tenderness and enlargement reduction, fatigue, **depression** and loss of libido were evaluated.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:353298 CAPLUS
DOCUMENT NUMBER: 136:350812
TITLE: GnRH analogues for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs
INVENTOR(S): Arnold, Susi; Reichler, Iris; Hubler, Madeleine
PATENT ASSIGNEE(S): University of Zurich, Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036144	A1	20020510	WO 2001-CH636	20011026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001095359	A5	20020515	AU 2001-95359	20011026
EP 1330257	A1	20030730	EP 2001-975948	20011026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001015067	A	20040406	BR 2001-15067		20011026
JP 2004512369	T2	20040422	JP 2002-538955		20011026
US 2004023878	A1	20040205	US 2003-415519		20030430
PRIORITY APPLN. INFO.:			EP 2000-811011	A	20001030
			WO 2001-CH636	W	20011026

IT **67392-87-4**, Drospirenone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 67392-87-4 CAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The use of at least one GnRH analog for the preparation of a medicament for the prevention and/or treatment of side effects of ovariectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed. The GnRH analog is selected from the group consisting of deslorelin acetate, goserelin acetate, nafarelin acetate, buserelin acetate, triptorelin acetate, gonadorelin acetate, leuprolid acetate, danazolum, Cetrorelix or mixts. thereof. The medicament can further comprise another active substance selected from the group consisting of an estrogenic agent, a partial estrogenic agent, a progestational agent, or mixts. thereof. The addnl. active ingredient can also be an α-adrenergic agonist, a β-adrenergic receptor blocking agent, a cholinergic receptor blocking compound, a cholinergic receptor stimulating drug, a smooth muscle relaxant, a nitric oxide synthase substrate, a nitric oxide donor, or mixts. thereof.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l13 1-4 ibib hitstr abs

L13 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:370645 CAPLUS
DOCUMENT NUMBER: 140:351119

09619493

TITLE: Use of progesterone or an agonist thereof for the inhibition of steroid synthesis
INVENTOR(S): Paust, Hans-Joachim; Mukhopadhyay, Amal K.; Patchev, Vladimir
PATENT ASSIGNEE(S): Jenapharm GmbH & Co. KG, Germany
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1415653	A2	20040506	EP 2003-25324	20031103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
DE 10251028	A1	20040519	DE 2002-10251028	20021101
JP 2004155783	A2	20040603	JP 2003-374115	20031104

PRIORITY APPLN. INFO.: DE 2002-10251028 A 20021101
IT **67392-87-4**, Drospirenone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of progesterone or an agonist thereof for the inhibition of steroid synthesis)
RN 67392-87-4 CAPLUS
CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The present invention concerns use of progesterone or a progesterone receptor agonist for production of a pharmaceutical agent for inhibiting steroid synthesis, in particular for inhibition of steroidogenic cute regulatory protein (StAR-protein).

L13 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:796500 CAPLUS
DOCUMENT NUMBER: 139:271458
TITLE: Pharmaceutical compositions and uses for hormone replacement therapy with estrogenic and progestogenic compounds coupled to an aromatase inhibitor

09619493

INVENTOR(S): Casper, Robert F.
PATENT ASSIGNEE(S): Jencap Research Ltd., Can.
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082299	A1	20031009	WO 2003-CA491	20030403

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-369629P P 20020403
US 2002-369707P P 20020403

IT **67392-87-4**, Drospirenone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and uses for hormone replacement therapy with estrogenic and progestogenic compds. coupled to an aromatase inhibitor)

RN 67392-87-4 CAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The present invention provides an improved pharmaceutical preparation, for administration to a female in need of hormone replacement therapy with substantially reduced breakthrough bleeding, comprising a plurality of doses wherein each dose comprises an amount of a substance exhibiting estrogenic activity and an amount of a substance exhibiting progestogenic activity and at least one aromatase inhibitor. The use of those compns. are exemplified on women presenting premature ovarian failure, normal

satisfactorily by administration in an extended regimen.
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:338374 CAPLUS
DOCUMENT NUMBER: 139:79293
TITLE: Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms
AUTHOR(S): Apter, D.; Borsos, A.; Baumgartner, W.; Melis, G.-B.; Vexiau-Robert, D.; Colligs-Hakert, A.; Palmer, M.; Kelly, S.
CORPORATE SOURCE: The Family Federation of Finland, Helsinki, 00101, Finland
SOURCE: European Journal of Contraception & Reproductive Health Care (2003), 8(1), 37-51
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **164017-31-6**, Yasmin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms)
RN 164017-31-6 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6

09619493

CMF C20 H24 O2

Absolute stereochemistry.



AB Oral contraception is the most widely used reversible contraceptive method. Continuous research over the past decades has led to a range of highly reliable, effective and safe oral contraceptives. Newly developed progestogens may also provide addnl. non-contraceptive health-related benefits that differentiate the products from each other. Women desiring contraception may thus choose from a wide range of oral contraceptives according to their individual needs. A variety of phys. and emotional changes have been linked to hormonal fluctuations during the menstrual cycle. To date, only very few studies have been performed on the impact of fluid retention-related symptoms on well-being and few data are hence available on suggested methods of measurement. This open, multicenter, uncontrolled study evaluated the effects of a combined preparation containing 3 mg drospirenone and 30 μg ethinylestradiol (Yasmin, Schering AG, Berlin, Germany) on general well-being and fluid-related symptoms in women experiencing psychol., behavioral and somatic **premenstrual** symptoms. The study was conducted over six 28-day cycles, with 336 subjects enrolled. A significant beneficial effect on psychol. general well-being, as measured by the Psychol. General Well-Being Index (PGWBI), was evident by cycle 3 and maintained at cycle 6. There was a significant reduction in both the incidence and severity of somatic symptoms associated with the menstrual cycle (abdominal bloating and breast tension) during treatment. Assessment by the investigator showed that 80% of subjects had improved on study treatment and 75% of subjects considered themselves satisfied with the study treatment. There was good agreement between the clinician and subject in their assessment of the treatment. Cycle control was very good and body weight remained stable or decreased slightly during the study. In conclusion, 3 mg drospirenone in combination with 30 μg ethinylestradiol has been shown to have a beneficial effect on psychol. general well-being, as measured by the PGWBI. Redns. in the incidence and severity of somatic symptoms associated with the menstrual cycle were also observed, suggesting a beneficial effect due to the antimineralocorticoid nature of drospirenone. To our knowledge, this is the first study on oral contraceptives which has used the PGWBI in this population. As quality of life is one of the least explored segments in oral contraceptive users, more studies should investigate the impact of oral contraceptives on quality of life and general well-being in this overall healthy population.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:293199 CAPLUS
DOCUMENT NUMBER: 139:30958

09619493

TITLE: Experiences with Yasmin : the acceptability of a novel oral contraceptive and its effect on well-being
AUTHOR(S): Mansour, D.
CORPORATE SOURCE: Community Gynaecology and Reproductive Health Care, Contraception and Sexual Health Services, Newcastle upon Tyne, UK
SOURCE: European Journal of Contraception & Reproductive Health Care (2002), 7(Suppl. 3), 35-41
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

IT **164017-31-6**, Yasmin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Yasmin, a novel oral contraceptive and its effect on well-being)

RN 164017-31-6 CAPLUS

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



AB A review. There are well over 100 million women using oral contraceptives world-wide; however, the number of women taking the pill differs from country to country. In the 1960s when 'the pill' was launched, most women wanted an effective, reversible contraceptive method. In the twenty-first century, they take these properties of oral contraceptives as given and now expect a number of non-contraceptive benefits including lighter and less painful periods, 'clear skin' and an overall improvement in well-being. Many oral contraceptives fall short of this ideal, with women discontinuing their pills because of perceived side-effects including weight gain, mood changes and breast tension. A new oral contraceptive has been developed to help fill this need. A review. It contains 3 mg drospirenone, a progestogen resembling endogenous progesterone, and 30 μg ethinylestradiol (DRSP/EE, Yasmin, Schering AG, Berlin, Germany). It has been shown to be highly effective in preventing pregnancies as well as providing good cycle control. Studies have suggested that rates of dysmenorrhea improved in women taking DRSP/EE as well as in women using an oral contraceptive containing 30 μg ethinylestradiol and desogestrel, but symptoms were more often mild or less often severe in the DRSP/EE group. Drospirenone is quite unique as it is derived from 17α-spirolactone and has antimineralocorticoid as well as antiandrogenic properties. The effect of DRSP/EE on skin has been evaluated in women with mild to moderate facial acne. A pos. effect on acne and seborrhea was observed, with the median acne lesion count decreasing by 62.5% from baseline to cycle 9, while seborrhea decreased by 25.1%. Further areas of research are focusing on **premenstrual** symptoms. A very recent European study has been completed to assess the effect of DRSP/EE on the general well-being and fluid-related symptoms over six treatment cycles in women desiring contraception. Overall, these results suggest that women who report **premenstrual** symptoms, including psychol. and/or somatic problems, before starting DRSP/EE, have improved scores when their Psychol. General Well-Being Index is measured and suffer fewer somatic symptoms. In conclusion, the combination of drospirenone with ethinylestradiol provides an effective and well-tolerated oral contraceptive with pos. effects on body weight, skin and **premenstrual** symptoms. These unique features of DRSP/EE may improve well-being and have a pos. effect on oral contraceptive continuation.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:293197 CAPLUS
DOCUMENT NUMBER: 139:30997
TITLE: Evaluation of a unique oral contraceptive (Yasmin) in the management of **premenstrual** dysphoric disorder
AUTHOR(S): Freeman, E. W.
CORPORATE SOURCE: Departments of Obstetrics/Gynecology and Psychiatry,

09619493

University of Pennsylvania, Philadelphia, PA, USA
SOURCE: European Journal of Contraception & Reproductive Health Care (2002), 7(Suppl. 3), 27-34
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **164017-31-6**, Yasmin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of oral contraceptive (Yasmin) in treatment of **premenstrual** dysphoric disorder)

RN 164017-31-6 CAPLUS

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.

09619493



AB Over three-quarters of women experience some phys. and emotional changes associated with the menstrual cycle. Irritability, tension, fatigue, depression, breast tenderness and bloating are among the most common **premenstrual** symptoms. Approx. 5-10% of women of childbearing age experience **premenstrual** symptoms to a degree that disrupts their functioning in the home or workplace and that meet criteria for **premenstrual** dysphoric disorder (PMDD). Serotonergic antidepressants are clearly effective for PMDD, with about 60% of subjects responding to this treatment in controlled studies. Oral contraceptives are commonly used to treat **premenstrual** symptoms but are an understudied intervention with no information on their efficacy for PMDD. The recent introduction of an oral contraceptive (Yasmin, Schering AG, Berlin, Germany), containing low-dose ethinylestradiol (EE) combined with a new progestogen, drospirenone (DRSP), may offer clin. efficacy for PMDD as a result of the unique pharmacol. profile of this progestogen, which is a spirolactone derivative with anti mineralocorticoid and antiandrogenic activity. A randomized, placebo-controlled study of DRSP/EE in women with PMDD found a consistently greater reduction of symptoms from baseline for all 22 **premenstrual** symptoms assessed (using the Calendar of **Premenstrual** Experiences, COPE) and for the four statistically derived symptom factors in the group taking DRSP/EE compared to the placebo group. For appetite, acne and food craving (factor 3), the difference between the DRSP/EE group and the placebo group was statistically significant ($p = 0.027$). These preliminary results suggest the beneficial effect of DRSP/EE on PMDD and offer an alternative class of medication that also provides the range of benefits of oral contraception for women with PMDD.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:225153 CAPLUS
DOCUMENT NUMBER: 138:362884
TITLE: Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on **premenstrual** symptomatology and health-related quality of life
AUTHOR(S): Borenstein, Jeff; Yu, Hsing-Ting; Wade, Sally; Chiou, Chiun-Fang; Rapkin, Andrea
CORPORATE SOURCE: Departments of Internal Medicine and Health Services Research (Zynx Health), Cedars-Sinai Health System, and Department of Obstetrics and Gynecology, University of California, Los Angeles, USA
SOURCE: Journal of Reproductive Medicine (2003), 48(2), 79-85
CODEN: JRPMAP; ISSN: 0024-7758
PUBLISHER: Science Printers and Publishers, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **164017-31-6**, Yasmin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of Yasmin, an oral contraceptive on **premenstrual** symptomatol. and health-related quality of life)

RN 164017-31-6 CAPLUS

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



AB Objective: To evaluate the effect of the oral contraceptive Yasmin (drospirenone, 3 mg, and ethinyl estradiol, 30 μg) (Berlex Labs., Wayne, New Jersey) on **premenstrual** symptomatol. and health-related quality of life (HRQoL). Study Design: Participating health care providers received 11,260 self-administered surveys for

distribution to women initiating use of Yasmin. Of these, 1,932 (17.2%) baseline surveys and 1,104 follow-up surveys (57.1%) were returned, with 858 (44.4%) of the returns evaluated as suitable for anal. Results: **Premenstrual** symptomatol., as measured with the neg. affect and water retention domains of the Moos Menstrual Distress Questionnaire (MDQ), significantly improved from baseline in all phases of the menstrual cycle (P =.000). All individual MDQ items improved significantly in the late luteal phase and during menses (P =.000), and the majority (76.9%) improved significantly in the remainder of the cycle (P <.05). Improvements were also observed in general sense of well-being (P <.05), impairment in usual activities due to **premenstrual** symptomatol. (P <.05) and Mental Component Summary scale (P =.000) but not the Phys. Component Summary scale of the Short Form-12 generic HRQoL instrument. Conclusion: These data support the effectiveness of Yasmin in reducing **premenstrual** symptomatol. and improving HRQoL and general sense of well-being.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:979744 CAPLUS
DOCUMENT NUMBER: 138:231829
TITLE: Quality of life issues: potential role for an oral contraceptive containing ethynylestradiol and drospirenone
AUTHOR(S): Dickerson, Vivian
CORPORATE SOURCE: Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, USA
SOURCE: Journal of Reproductive Medicine (2002), 47(11, Suppl.), 985-993
CODEN: JRPMAP; ISSN: 0024-7758
PUBLISHER: Science Printers and Publishers, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
IT **164017-31-6**, Yasmin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral contraceptive containing ethynylestradiol and drospirenone potential for improving acne and seborrhea and **premenstrual** syndrome)
RN 164017-31-6 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



AB A review on the antiandrogenic and antimineralocorticoid activities of the new progestogen drospirenone that makes a combined oral contraceptive containing this compound with ethynylestradiol (Yasmin) of special benefit in improving quality of life. Drospirenone's antiandrogenic activity, for example, makes it effective in reducing acne and seborrhea. Drospirenone's antimineralocorticoid activity aids in reducing some of the most bothersome symptoms associated with the **premenstrual** phase of the menstrual cycle.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:486123 CAPLUS
DOCUMENT NUMBER: 137:52386
TITLE: Preparation of compositions of estrogen-cyclodextrin complexes
INVENTOR(S): Backensfeld, Thomas; Heil, Wolfgang
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1216713	A1	20020626	EP 2000-610135	20001220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002049675	A1	20020627	WO 2001-IB2605	20011220
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002019418	A5	20020701	AU 2002-19418	20011220
US 2002173487	A1	20021121	US 2001-22845	20011220
EP 1353700	A1	20031022	EP 2001-271231	20011220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300298	A	20031215	EE 2003-298	20011220
BR 2001016417	A	20031230	BR 2001-16417	20011220
JP 2004518656	T2	20040624	JP 2002-551012	20011220
NO 2003002805	A	20030820	NO 2003-2805	20030619

PRIORITY APPLN. INFO.:

EP 2000-610135	A	20001220
US 2000-256484P	P	20001220
WO 2001-IB2605	W	20011220

IT **67392-87-4**, Drospirenone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of compns. of estrogen-cyclodextrin complexes)

RN 67392-4 CAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Clathrates between cyclodextrin and an estrogen in pharmaceutical compns. confer an increased stability to the estrogen. The estrogen, ethinylestradiol has an increased resistance to oxidative degradation when

part of the inclusion complex as measured at an array of temps. and relative humidity levels. Compns. formulated to limit the amount of oxidants also increase the stability of the estrogen. Pharmaceutical compns. comprising an estrogen for female contraception, hormone replacement therapy, menopause, or acne have longer shelf-life and may require smaller amts. of the drug. Thus, film-coated tablets were prepared from composition was prepared from ethinylestradiol-β-cyclodextrin complex, drospirenone, lactose, corn starch, microcryst. cellulose, starch-1500, and Mg stearate. The content of the ethinylestradiol-β-cyclodextrin complex was 98.9% after storage at 40° and 75% relative humidity.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:138754 CAPLUS
DOCUMENT NUMBER: 136:304199
TITLE: A new monophasic oral contraceptive containing drospirenone: Effect on **premenstrual** symptoms
AUTHOR(S): Brown, Candace; Ling, Frank; Wan, Jim
CORPORATE SOURCE: Departments of Pharmacy Practice, Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, TN, 38002, USA
SOURCE: Journal of Reproductive Medicine (2002), 47(1), 14-22
CODEN: JRPMAP; ISSN: 0024-7758
PUBLISHER: Science Printers and Publishers, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **67392-87-4**, Drospirenone
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drospirenone containing monophasic oral contraceptive effect on **premenstrual** symptoms)
RN 67392-87-4 CAPLUS
CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The aim of this study was to determine whether a new monophasic oral contraceptive containing drospirenone/ethinyl estradiol reduces **premenstrual** symptoms. In an open-label study measuring

intrasubject changes in **premenstrual** symptoms and comparing effects between women who were new users of oral contraceptives and those who switched from previous contraceptives, ethinyl estradiol (30 μg) and drospirenone (3 mg) were administered for 13 menstrual cycles to 326 healthy women aged 18-35 yr. Subjects completed the 23-item Women's Health Assessment Questionnaire at baseline and at the end of the sixth cycle. At the end of cycle 6, **premenstrual** and menstrual symptom scores on the neg. affect and water retention scales were reduced significantly relative to baseline, as was increased appetite during the **premenstrual** and menstrual phases. Similar improvements were seen among new users of hormonal contraceptives and those who switched from previous contraceptives. Impaired concentration scale scores were not significantly reduced from baseline, and assessments of undesired hair changes and feelings of well-being did not change appreciably. An oral contraceptive containing drospirenone/ethinyl estradiol may reduce the **premenstrual** symptoms of neg. affect, water retention and increased appetite.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:159234 CAPLUS
DOCUMENT NUMBER: 134:275892
TITLE: The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being
AUTHOR(S): Boschitsch, E.; Skarabis, H.; Wuttke, W.; Heithecker, R.
CORPORATE SOURCE: Ambulatorium Klimax, Vienna, A-1060, Austria
SOURCE: European Journal of Contraception & Reproductive Health Care (2000), 5(Suppl. 3), 34-40
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **164017-31-6**, Yasmin
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acceptability of oral contraceptive containing drospirenone and its effect on well-being in women)
RN 164017-31-6 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



AB Low-dose combined oral contraceptives are generally well tolerated and represent an excellent reversible form of contraception that is suitable for most women. Certain aspects of the clin. profile of combined oral contraceptives, such as intermenstrual bleeding and a tendency to weight gain, are, however, known to have an adverse effect on compliance, which may in a few women lead to contraceptive failure or pill discontinuation. Conversely, factors that have a pos. effect, such as relief from the symptoms of **premenstrual** syndrome, can enhance compliance. An oral contraceptive that minimizes the adverse and enhances the pos. effects would, therefore, be likely to improve compliance. Recently, a new combined oral contraceptive containing 30 μg ethinylestradiol and 3 mg drospirenone (Yasmin, EE/DRSP) has been developed. The pharmacol. profile of drospirenone is very similar to that of natural progesterone; in particular, it has antimineralocorticoid activity. This counteracts estrogen-mediated fluid retention, resulting in stable or slightly lowered body weight In addition, drospirenone has antiandrogenic activity and therefore a pos. effect on skin conditions. Present data also indicate that EE/DRSP has a favorable effect on the symptoms of **premenstrual** syndrome. In order to evaluate whether the pos. effects of drospirenone on body weight, skin and the symptoms of **premenstrual** syndrome are also observed on well-being, a survey was carried out. This asked women who had been involved in two major clin. trials how they felt after these trials had

ended, in comparison with the study periods when they were taking EE/DRSP or a combined oral contraceptive containing 30 μg ethinylestradiol/150 μg desogestrel (Marvelon, EE/DSG). The returned questionnaires demonstrated that, with respect to their disposition before and during menses, women who had taken EE/DRSP felt worse after the trial had ended and they had returned to taking a conventional preparation This was also evident on the basis of their body wts. and the condition of their skin and hair. These results from clin. trials with EE/DRSP indicate that it is a well-tolerated combined oral contraceptive that has a pos. effect on body weight, skin and the symptoms of **premenstrual** syndrome. Overall, the combination of 30 μg ethinylestradiol/3 mg drospirenone appears to improve specific aspects associated with feelings of well-being, which may result in better compliance.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:573249 CAPLUS
DOCUMENT NUMBER: 133:276507
TITLE: A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel
AUTHOR(S): Foidart, J. -M.; Wuttke, W.; Bouw, G. M.; Gerlinger, C.; Heithecker, R.
CORPORATE SOURCE: Department of Gynecology and Obstetrics, University of Liege, Liege, 4000, Belg.
SOURCE: European Journal of Contraception & Reproductive Health Care (2000), 5(2), 124-134
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **164017-31-6**, Yasmin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(contraceptive reliability and cycle control and tolerance of monophasic oral contraceptives containing either drospirenone or desogestrel)
RN 164017-31-6 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



AB To assess the contraceptive reliability, cycle control and tolerance of a new monophasic oral contraceptive (Yasmin) containing 30 μg ethinylestradiol and 3 mg drospirenone and compare it with a preparation containing an equal dose of ethinylestradiol combined with 150 μg desogestrel (Marvelon). A multicenter, open-label, randomized study was carried out in 26 European centers. Contraceptive efficacy, cycle control and tolerance (including body weight, blood pressure and heart rate) were assessed over 26 cycles, plus a 3-mo follow-up period. Of 900 women who were randomized, 887 started treatment and 627 completed the 26 cycles plus follow-up (310 in the ethinylestradiol/drospirenone group and 317 in the ethinylestradiol/desogestrel group). Both study prepns. were found to be effective with regard to contraceptive reliability and cycle control was good. There were six pregnancies (three in each group), but none were considered to have been the result of method failures. The subjective and objective tolerances were good in both groups. A statistically significant difference was found in body weight changes between the two groups. While there was an increase in mean body weight in the ethinylestradiol/desogestrel group from cycle 5 onward, the mean body weight per cycle in the ethinylestradiol/drospirenone group was slightly below the baseline value throughout the study. The incidence of **premenstrual** symptoms was higher in the ethinylestradiol/drospirenone group than in the

ethinylestradiol/desogestrel group during the 6 mo prior to the study, but lower during treatment. The rates of dysmenorrhea were identical under both treatments but the symptoms were more often mild and less often severe in the ethinylestradiol/drospirenone group. The combination of 30 μg ethinylestradiol combined with 3 mg drospirenone provides effective oral contraception and good cycle control, and is well tolerated. Ethinylestradiol/drospirenone had a more favorable effect on body weight than. Ethinylestradiol/desogestrel, with the mean body weight remaining lower than baseline for the majority of the women.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:430231 CAPLUS
DOCUMENT NUMBER: 129:77031
TITLE: Therapeutic gestagens for **premenstrual** dysphoric disorder
INVENTOR(S): Nashed, Norman
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: Ger. Offen., 4 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19654609	A1	19980625	DE 1996-19654609	19961220
WO 9827929	A2	19980702	WO 1997-DE3032	19971222
WO 9827929	A3	19981105		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9859810	A1	19980717	AU 1998-59810	19971222

PRIORITY APPLN. INFO.: DE 1996-19654609 19961220
WO 1997-DE3032 19971222

IT **67392-87-4**, Drospirenone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic gestagens for **premenstrual** dysphoric disorder)
RN 67392-87-4 CAPLUS
CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Gestagens such as drospirenone, cyproterone acetate, and dienogest (optionally in combination with natural or synthetic estrogens such as estradiol or ethynylestradiol) are useful in preparation of medications for treatment of **premenstrual** dysphoric disorder, possibly owing to their antiandrogenic action. Thus, women with **premenstrual** dysphoric disorder, treated daily with 3 mg drospirenone and 30 μg ethynylestradiol orally on days 1-21 of the menstrual cycle for 4-6 cycles, showed a lessening of symptoms related to mood, appetite, sleep, etc.

```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:H
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   136.70     154.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -13.97     -13.97

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:45:30 ON 09 JUL 2004
```

menopause and ovariectomy removed following endometriosis. Effects on breast tenderness and enlargement reduction, fatigue, **depression** and loss of libido were evaluated.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:293197 CAPLUS
DOCUMENT NUMBER: 139:30997
TITLE: Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder
AUTHOR(S): Freeman, E. W.
CORPORATE SOURCE: Departments of Obstetrics/Gynecology and Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
SOURCE: European Journal of Contraception & Reproductive Health Care (2002), 7(Suppl. 3), 27-34
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **164017-31-6**, Yasmin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of oral contraceptive (Yasmin) in treatment of premenstrual dysphoric disorder)
RN 164017-31-6 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



AB Over three-quarters of women experience some phys. and emotional changes associated with the menstrual cycle. Irritability, tension, fatigue, **depression**, breast tenderness and bloating are among the most common premenstrual symptoms. Approx. 5-10% of women of childbearing age experience premenstrual symptoms to a degree that disrupts their functioning in the home or workplace and that meet criteria for premenstrual dysphoric disorder (PMDD). Serotonergic antidepressants are clearly effective for PMDD, with about 60% of subjects responding to this treatment in controlled studies. Oral contraceptives are commonly used to treat premenstrual symptoms but are an understudied intervention with no information on their efficacy for PMDD. The recent introduction of an oral contraceptive (Yasmin, Schering AG, Berlin, Germany), containing low-dose ethinylestradiol (EE) combined with a new progestogen, drospirenone (DRSP), may offer clin. efficacy for PMDD as a result of the unique pharmacol. profile of this progestogen, which is a spirolactone derivative with anti mineralocorticoid and antiandrogenic activity. A randomized, placebo-controlled study of DRSP/EE in women with PMDD found a consistently greater reduction of symptoms from baseline for all 22 premenstrual symptoms assessed (using the Calendar of Premenstrual Experiences, COPE) and for the four statistically derived symptom factors in the group taking DRSP/EE compared to the placebo group. For appetite, acne and food craving (factor 3), the difference between the DRSP/EE group and the placebo group was statistically significant ($p = 0.027$). These preliminary results suggest the beneficial effect of DRSP/EE on PMDD and offer an alternative class of medication that also provides the range of benefits of oral contraception for women with PMDD.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:353298 CAPLUS
DOCUMENT NUMBER: 136:350812
TITLE: GnRH analogues for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs
INVENTOR(S): Arnold, Susi; Reichler, Iris; Hubler, Madeleine
PATENT ASSIGNEE(S): University of Zurich, Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002036144	A1	20020510	WO 2001-CH636	20011026	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2001095359	A5	20020515	AU 2001-95359	20011026	
EP 1330257	A1	20030730	EP 2001-975948	20011026	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001015067	A	20040406	BR 2001-15067	20011026	
JP 2004512369	T2	20040422	JP 2002-538955	20011026	
US 2004023878	A1	20040205	US 2003-415519	20030430	
PRIORITY APPLN. INFO.:			EP 2000-811011	A 20001030	
			WO 2001-CH636	W 20011026	

IT **67392-87-4**, Drospirenone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH analogs in combination with other active ingredients for treatment of urinary incontinence and other side effects associated with ovariectomy or reproductive senescence in humans and dogs)

RN 67392-87-4 CAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The use of at least one GnRH analog for the preparation of a medicament for the prevention and/or treatment of side effects of ovariectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed. The GnRH analog is selected from the group consisting of deslorelin acetate, goserelin acetate, nafarelin acetate, buserelin acetate, triptorelin acetate, gonadorelin acetate, leuprolid acetate, danazolum, Cetrorelix or mixts. thereof. The medicament can further comprise another active substance selected from the group consisting of an estrogenic agent, a partial estrogenic agent, a progestational agent, or mixts.

thereof. The addnl. active ingredient can also be an α-adrenergic agonist, a β-adrenergic receptor blocking agent, a cholinergic receptor blocking compound, a cholinergic receptor stimulating drug, a smooth muscle relaxant, a nitric oxide synthase substrate, a nitric oxide donor, or mixts. thereof.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l14 ibib hitstr abs

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:293193 CAPLUS
DOCUMENT NUMBER: 139:30957
TITLE: Yasmin : the reason why
AUTHOR(S): Thorneycroft, I. H.
CORPORATE SOURCE: Mobile Ob-Gyn Center, Lunar Research and Department of Obstetrics and Gynecology, University of South Alabama College of Medicine, AL, USA
SOURCE: European Journal of Contraception & Reproductive Health Care (2002), 7(Suppl. 3), 13-18
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
IT **164017-31-6**, Yasmin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Yasmin as a oral contraceptive)
RN 164017-31-6 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



09619493

CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



AB A review. Oral contraceptives have been available for a little over 40 yr and, during that time, many different formulations have been introduced. There have been dramatic dosage redns. of both the estrogen and progestogen components and various progestogens have been introduced over time. The properties of most progestogens used in oral contraceptives are very similar, differing mainly in potency. Oral contraceptives with progestogens having new and unique properties are needed. World-wide, around 20-30% of women of childbearing age use oral contraceptives and their use declines after the age of 35 yr, with an accompanying increase in the rates of unintended pregnancy and elective termination. Incorrect use likewise gives rise to high unintended pregnancy rates. Use in Europe is higher than in other regions. Discontinuation because of unwanted effects and misperceptions is very common. Common misperceptions that prevent women from initiating oral contraceptive use are weight gain, cancer risks and that bleeding indicates a significant problem. Unwanted effects that commonly give rise to discontinuation are bleeding, nausea, weight gain, mood changes, breast tenderness and **headaches.** Discontinuation rates are high, particularly in the first year, and adolescents have the highest rates of discontinuation. Correct consistent use must be encouraged by taking pills at a regular time each day and by reinforcing that bleeding and other unwanted effects are not medically serious. Reinforcement of the non-contraceptive health benefits is very important and it needs to be emphasized that long-term use enhances these non-contraceptive benefits. Most non-contraceptive benefits are due to the progestogen component and its inhibition of ovulation. The new drospirenone-containing oral contraceptive (Yasmin, Schering AG, Berlin, Germany) offers the traditional non-contraceptive benefits; however, due to its unique antimineralocorticoid and antiandrogenic properties, new and unique benefits have been observed Acne is well controlled, as would be expected from its inhibition of ovulation, antiandrogenic activity and lack of attenuation of the estrogen-mediated increase in sex hormone binding globulin. Its antimineralocorticoid activity gives rise to a reduction in fluid-related symptoms. The oral contraceptive containing 3 mg drospirenone with 30 μg ethinylestradiol (DRSP/EE) has excellent efficacy since drospirenone is a potent progestogen, the corrected Pearl index being 0.09. This index is lower than those of many other oral contraceptives. Cycle control is excellent and comparable to that experienced with other oral contraceptives. A significant and consistent weight loss was seen with DRSP/EE compared to a reference preparation containing desogestrel. Day-to-day compliance and the duration of intake of an oral

contraceptive are dependent on the woman's satisfaction with the pill she is taking. DRSP/EE meets these expectations and, with its new and unique non-contraceptive benefits, offers a real new choice to women.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l15 ibib hitstr abs

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:293193 CAPLUS
DOCUMENT NUMBER: 139:30957
TITLE: Yasmin : the reason why
AUTHOR(S): Thorneycroft, I. H.
CORPORATE SOURCE: Mobile Ob-Gyn Center, Lunar Research and Department of Obstetrics and Gynecology, University of South Alabama College of Medicine, AL, USA
SOURCE: European Journal of Contraception & Reproductive Health Care (2002), 7(Suppl. 3), 13-18
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
IT **164017-31-6**, Yasmin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Yasmin as a oral contraceptive)
RN 164017-31-6 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-, mixt. with (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione (9CI) (CA INDEX NAME)

CM 1

CRN 67392-87-4
CMF C24 H30 O3

Absolute stereochemistry.



CM 2

CRN 57-63-6
CMF C20 H24 O2

Absolute stereochemistry.



AB A review. Oral contraceptives have been available for a little over 40 yr and, during that time, many different formulations have been introduced. There have been dramatic dosage redns. of both the estrogen and progestogen components and various progestogens have been introduced over time. The properties of most progestogens used in oral contraceptives are very similar, differing mainly in potency. Oral contraceptives with progestogens having new and unique properties are needed. World-wide, around 20-30% of women of childbearing age use oral contraceptives and their use declines after the age of 35 yr, with an accompanying increase in the rates of unintended pregnancy and elective termination. Incorrect use likewise gives rise to high unintended pregnancy rates. Use in Europe is higher than in other regions. Discontinuation because of unwanted effects and misperceptions is very common. Common misperceptions that prevent women from initiating oral contraceptive use are weight gain, cancer risks and that bleeding indicates a significant problem. Unwanted effects that commonly give rise to discontinuation are bleeding, nausea, weight gain, mood changes, breast tenderness and **headaches.** Discontinuation rates are high, particularly in the first year, and adolescents have the highest rates of discontinuation. Correct consistent use must be encouraged by taking pills at a regular time each day and by reinforcing that bleeding and other unwanted effects are not medically serious. Reinforcement of the non-contraceptive health benefits is very important and it needs to be emphasized that long-term use enhances these non-contraceptive benefits. Most non-contraceptive benefits are due to the progestogen component and its inhibition of ovulation. The new drospirenone-containing oral contraceptive (Yasmin, Schering AG, Berlin, Germany) offers the traditional non-contraceptive benefits; however, due to its unique antimineralocorticoid and antiandrogenic properties, new and unique benefits have been observed Acne is well controlled, as would be expected from its inhibition of ovulation, antiandrogenic activity and lack of attenuation of the estrogen-mediated increase in sex hormone binding globulin. Its antimineralocorticoid activity gives rise to a reduction in fluid-related symptoms. The oral contraceptive containing 3 mg drospirenone with 30 μg ethinylestradiol (DRSP/EE) has excellent efficacy since drospirenone is a potent progestogen, the corrected Pearl index being 0.09. This index is lower than those of many other oral contraceptives. Cycle control is excellent and comparable to that experienced with other oral contraceptives. A significant and consistent weight loss was seen with DRSP/EE compared to a reference preparation containing desogestrel. Day-to-day compliance and the duration of intake of an oral contraceptive are dependent on the woman's satisfaction with the pill she is taking. DRSP/EE meets these expectations and, with its new and unique

non-contraceptive benefits, offers a real new choice to women.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l17 1-11 ibib hitstr abs

L17 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:990276 CAPLUS
DOCUMENT NUMBER: 140:23409
TITLE: Use of an oral contraceptive containing drospirenone in an extended regimen
AUTHOR(S): Sillem, M.; Schneidereit, R.; Heithecker, R.; Mueck, A. O.
CORPORATE SOURCE: Gynecological Clinic, Aschaffenburg, Germany
SOURCE: European Journal of Contraception & Reproductive Health Care (2003), 8(3), 162-169
CODEN: ECRCFK; ISSN: 1362-5187
PUBLISHER: Parthenon Publishing Group Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **67392-87-4**, Drospirenone
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of an oral contraceptive containing drospirenone in an extended regimen)
RN 67392-87-4 CAPLUS
CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB As well as providing reliable contraception, modern low-dose oral contraceptives may offer some non-contraceptive advantages. Pos. effects on problems such as edema with weight increase and breast tenderness, bloating, dysmenorrhea, and an improvement in skin and hair condition have been reported in several studies using an oral contraceptive containing drospirenone. If these disorders are cycle-dependent, use of the contraceptive in an extended regimen may be of addnl. benefit. The study reported in this paper followed 1433 women, 175 of whom took the drospirenone-containing pill continuously for between 42 and 126 days. Some symptoms of the **premenstrual** syndrome were influenced very

09619493

=> s spironolactone
L23 13 SPIRONOLACTONE

=> d l23 1-4

L23 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN
RN 149359-12-6 REGISTRY
CN Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, γ-lactone, (7α,17α)-, compd. with benzene (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Spiro[17H-cyclopenta[a]phenanthrene-17,2'(5'H)-furan], pregn-4-ene-21-carboxylic acid deriv.
OTHER NAMES:
CN Aldactone-benzene solvate
CN **Spironolactone-benzene solvate**
FS STEREOSEARCH
MF C24 H32 O4 S . C6 H6
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PROC (Process); PRP (Properties)

CM 1

CRN 71-43-2
CMF C6 H6

CM 2

CRN 52-01-7
CMF C24 H32 O4 S

Absolute stereochemistry.



7/9/04

09619493

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN
RN 149359-11-5 REGISTRY
CN Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, γ-lactone, (7α,17α)-, compd. with ethyl acetate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic acid ethyl ester, compd. with (7α,17α)-7-(acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone (1:1) (9CI)
CN Spiro[17H-cyclopenta[a]phenanthrene-17,2'(5'H)-furan], pregn-4-ene-21-carboxylic acid deriv.
OTHER NAMES:
CN Aldactone-ethyl acetate solvate
CN **Spironolactone-ethyl acetate solvate**
FS STEREOSEARCH
MF C24 H32 O4 S . C4 H8 O2
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PROC (Process); PRP (Properties)

CM 1

CRN 141-78-6
CMF C4 H8 O2

Et—O—Ac

CM 2

CRN 52-01-7
CMF C24 H32 O4 S

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

7/9/04

L23 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN
RN 149359-10-4 REGISTRY
CN Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, γ-lactone, (7α,17α)-, compd. with ethanol (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanol, compd. with (7α,17α)-7-(acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone (1:1) (9CI)
CN Spiro[17H-cyclopenta[a]phenanthrene-17,2'(5'H)-furan], pregn-4-ene-21-carboxylic acid deriv.
OTHER NAMES:
CN Aldactone ethanolate
CN **Spironolactone ethanolate**
FS STEREOSEARCH
MF C24 H32 O4 S . C2 H6 O
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PROC (Process); PRP (Properties)

CM 1

CRN 64-17-5
CMF C2 H6 O

H_3C-CH_2-OH

CM 2

CRN 52-01-7
CMF C24 H32 O4 S

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2004 ACS on STN
RN 149359-09-1 REGISTRY
CN Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-,

γ-lactone, (7α,17α)-, compd. with methanol (1:1) (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Methanol, compd. with (7α,17α)-7-(acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone (1:1) (9CI)
CN Spiro[17H-cyclopenta[a]phenanthrene-17,2'(5'H)-furan], pregn-4-ene-21-carboxylic acid deriv.
OTHER NAMES:
CN Aldactone methanolate
CN **Spironolactone methanolate**
FS STEREOSEARCH
MF C24 H32 O4 S . C H4 O
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PROC (Process); PRP (Properties)

CM 1

CRN 67-56-1
CMF C H4 O

$H_3C—OH$

CM 2

CRN 52-01-7
CMF C24 H32 O4 S

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>